Ultrahigh-field MPRAGE Magnetic Resonance Angiography at 7.0T in @entity1 with XXXX .

@entity1 @entity64 @entity66 @entity7025 @entity1054
OBJECTIVES: @entity1054 ( @entity1054 ) magnetic-resonance-angiography (MRA) identifies vessel pathology in @entity66 . At 7.0T, the clinical performance of @entity1054 -MRA is constrained owing to radio frequency power deposition. We studied the diagnostic value of whole-brain MPRAGE-based MRA as an alternative imaging technique in comparison to the clinical standard 3.0T @entity1054 -MRA. METHODS: @entity1 with @entity64 and/or @entity7025 were included. @entity1054 -MRA was performed at 3.0T and MPRAGE-MRA at 7.0T. Two radiologists rated the MRAs independently for overall quality and local arterial segment visualization. The identification of steno-occlusive pathology was reported for each protocol. RESULTS: In 18 @entity1 (9 females; 6 @entity1 with moya-moya) 7.0T MPRAGE-MRA provided better overall image quality and better distinction of small structures compared to 3.0T @entity1054 -MRA. These findings were pronounced in the proximal segments of the anterior cerebral artery (A1), middle cerebral artery (M1, M2), posterior cerebral artery (P1) and the posterior communicating artery. Seven steno-occlusive findings were identified by both imaging protocols. CONCLUSIONS: For clinical studies using ultrahigh field MRI, 7.0T MPRAGE-MRA provides a suitable alternative to @entity1054 -MRA imaging to identify brain vessel pathology and yields simultaneous structural brain imaging within clinically feasible acquisition times.
